FDA approves Zydelig for CLL, SLL, follicular lymphoma

  • July 23, 2014

The FDA today approved the PI3 kinase delta inhibitor idelalisib as monotherapy for patients with follicular B-cell non-Hodgkin’s lymphoma and small lymphocytic lymphoma, and also as part of combination therapy with rituximab for patients with high-risk relapsed or refractory chronic lymphocytic leukemia.

The FDA granted traditional approval to idelalisib (Zydelig, Gilead) for the treatment of relapsed/refractory CLL.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
More»
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today